The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi ® /Minjuvi ® ) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGB...
Incyte's Pivotal frontMIND Trial Showed Tafasitamab Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
